Hepatitis C patent suit
This article was originally published in The Gray Sheet
Roche does not have "express or implied license rights" to hepatitis C virus (HCV) technology owned by Chiron, a San Francisco federal court rules. Announced Aug. 2 by Chiron, the June 23 ruling follows cross-motions for summary judgment. Filed in February 1998, the suit alleges that Roche's HCV assays infringe Chiron patents relating to nucleic acid testing (NAT) methods that use polynucleotides for detecting HCV in blood. Roche had claimed that it obtained a license to the Chiron technology in connection with its acquisition of Cetus Corporation's NAT business, Chiron says. Roche plans to appeal the decision
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.